



Contents lists available at ScienceDirect

EBioMedicine

journal homepage: www.elsevier.com/locate/ebiom

Corrigendum

Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens”



Laurens Liesenborghs^{a,b,*}, Isabel Spriet^c, Dirk Jochmans^a, Ann Belmans^d, Iwein Gyselinck^e, Laure-Anne Teuwen^f, Sebastiaan ter Horst^a, Erwin Dreesen^g, Tatjana Geukens^h, Matthias M. Engelenⁱ, Ewout Landeloos^j, Vincent Geldhof^f, Helga Ceunen^k, Barbara Debaveyeⁱ, Bert Vandenbergⁱ, Lorenz Van der Linden^c, Sofie Jacobs^a, Lana Langendries^a, Robbert Boudewijns^a, Thuc Nguyen Dan Do^a, Winston Chiu^a, Xinyu Wang^a, Xin Zhang^a, Birgit Weynand^l, Thomas Vanasscheⁱ, Timothy Devos^m, Geert Meyfroidtⁿ, Wim Janssens^e, Robin Vos^e, Pieter Vermeersch^o, Joost Wauters^p, Geert Verbeke^d, Paul De Munter^k, Suzanne J.F. Kaptein^a, Joana Rocha-Pereira^a, Leen Delang^a, Eric Van Wijngaerden^{k,1,*}, Johan Neyts^{a,1}, Peter Verhamme^{i,1}

^a Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium

^b The Outbreak Research Team, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

^c Pharmacy Department University Hospitals Leuven and Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium

^d KU Leuven University of Leuven & Universiteit Hasselt, I-BioStat, Leuven, Belgium

^e Department of Respiratory Diseases, UZ Leuven and CHROMETA, Research group BREATHE, KU Leuven, Leuven, Belgium

^f Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium

^g Clinical Pharmacology and Pharmacotherapy Unit, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium

^h Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, Belgium

ⁱ Department of Cardiovascular Sciences, UZ and KU Leuven, Belgium

^j Department of Oncology, Laboratory for molecular Cancer biology, VIB-KU Leuven, Belgium

^k Department of General Internal Medicine, UZ Leuven and Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium

^l Translational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven, Belgium

^m Department of Hematology, UZ Leuven and Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Belgium

ⁿ Department and Laboratory of Intensive Care Medicine, UZ and KU Leuven, Belgium

^o Department of Cardiovascular Sciences and Clinical Department of Laboratory Medicine, KU Leuven, Belgium

^p Medical Intensive Care Unit, UZ Leuven and Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium

The authors of this Research Paper would like to update the Acknowledgements section. The new text of this section is as follows:

Acknowledgments

This project has received funding from the Covid-19-Fund KU Leuven / University Hospitals Leuven, the COVID-19 call of the Research Foundation - Flanders (FWO) (grant G0G4820N), the European Union's Horizon 2020 research and innovation program (Grant 101,003,627, Swift COronavirus therapeutics REsponse project) and the Bill and Melinda Gates Foundation (Grant INV-00,636). LLI is member of the Institute of Tropical Medicine's Outbreak Research Team which is financially supported by the Department of Economy, Science and Innovation (EWI) of the Flemish government. BV is supported by a research grant of the Frans Van de Werf Fund for Clinical Cardiovascular Research. P. Verhamme, TV, P. Vermeersch are senior clinical investigators of the FWO. We thank Johnson & Johnson for determining drug concentrations in hamster samples and for providing guidance on the dosing. We thank Lindsey Bervoets, Carolien De Keyzer, Elke Maas and Jasper Rymenants for the technical support with the animal experiments.

TNDD is funded by the Horizon 2020 grant OrganoVIR 812,673 on the project 'Organoids for Virus Research - An innovative training-ITN programme'. XW and XZ received funding of the China Scholarship Council (CSC) (grant number 201,806,170,087 and 201,906,170,033). Part of this research work was performed using the 'Caps-It' research infrastructure (project ZW13-02) that was financially supported by the Hercules Foundation (FWO) and Rega Foundation, KU Leuven.

DOI of original article: <http://dx.doi.org/10.1016/j.ebiom.2021.103288>.

* Corresponding author at: Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

E-mail address: lliesenborghs@itg.be (L. Liesenborghs).

¹ These authors contributed equally to this work.